Amarin Corporation (AMRN) Selloff on Vascepta Appeal Denial Has Little Impact on Number Kneejerk Selloff is Buying Opportunity - Northland Capital Markets
Tweet Send to a Friend
Northland Capital Markets analyst Carl Byrnes reiterated an Outperform rating and $15.00 price target on Amarin Corporation (NASDAQ: AMRN) noting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
